Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib ...

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

A three-drug regimen involving a PD-L1 inhibitor and two targeted agents was active and safe for treating the diffuse large B-cell lymphoma (DLBCL) variant of Richter transformation, the phase II ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...